ABDX vs. AGL, YGEN, PRM, GDR, VRCI, GENI, DMTR, LLAI, LLA, and IDHC
Should you be buying Abingdon Health stock or one of its competitors? The main competitors of Abingdon Health include ANGLE (AGL), Yourgene Health (YGEN), Proteome Sciences (PRM), genedrive (GDR), Verici Dx (VRCI), GENinCode (GENI), Deepmatter Group (DMTR), LungLife AI (LLAI), LLA.L,0P0001T9GN,0 (LLA), and Integrated Diagnostics (IDHC). These companies are all part of the "diagnostics & research" industry.
Abingdon Health vs.
Abingdon Health (LON:ABDX) and ANGLE (LON:AGL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, community ranking, dividends and analyst recommendations.
In the previous week, Abingdon Health's average media sentiment score of 1.02 beat ANGLE's score of 0.00 indicating that Abingdon Health is being referred to more favorably in the media.
33.5% of Abingdon Health shares are held by institutional investors. Comparatively, 18.8% of ANGLE shares are held by institutional investors. 48.9% of Abingdon Health shares are held by company insiders. Comparatively, 16.2% of ANGLE shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
ANGLE has a consensus price target of GBX 40, indicating a potential upside of 362.43%. Given ANGLE's stronger consensus rating and higher probable upside, analysts plainly believe ANGLE is more favorable than Abingdon Health.
Abingdon Health has a net margin of -20.72% compared to ANGLE's net margin of -890.91%. Abingdon Health's return on equity of -62.56% beat ANGLE's return on equity.
ANGLE received 183 more outperform votes than Abingdon Health when rated by MarketBeat users.
Abingdon Health has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500. Comparatively, ANGLE has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500.
Abingdon Health has higher revenue and earnings than ANGLE. Abingdon Health is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.
Summary
Abingdon Health beats ANGLE on 9 of the 16 factors compared between the two stocks.
Get Abingdon Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABDX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart
Abingdon Health Competitors List
Related Companies and Tools
This page (LON:ABDX) was last updated on 5/2/2025 by MarketBeat.com Staff